Glykos focuses on the development of best-in-class antibody-drug conjugates (ADCs) with an expanded therapeutic window. We are dedicated to creating treatments that not only increase survival rates but also enhance the quality of life for cancer patients. Leveraging our in-house developed technologies, we have established a next-generation antibody-drug conjugate platform, leading to the production of more effective and better...
Glykos focuses on the development of best-in-class antibody-drug conjugates (ADCs) with an expanded therapeutic window. We are dedicated to creating treatments that not only increase survival rates but also enhance the quality of life for cancer patients. Leveraging our in-house developed technologies, we have established a next-generation antibody-drug conjugate platform, leading to the production of more effective and better-tolerated ADCs. We are open to collaboration with pharmaceutical partners and antibody developers, emphasizing our commitment to advancing innovative solutions in the field of cancer therapeutics.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.